Oncolytic vesicular stomatitis virus (VSV) engineered to co-express

Class

Oncolytic vesicular stomatitis virus (VSV) engineered to co-express interferon-beta and the sodium-iodide symporter (NIS) (Vyriad Voyager-V1 platform)

Pathway

Direct viral oncolysis plus type-I-interferon-mediated antitumor immunity

Notes

original target text: Oncolytic vesicular stomatitis virus (VSV) engineered to co-express interferon-beta and the sodium-iodide symporter (NIS) (Vyriad Voyager-V1 platform)

This mechanism refers to a genetically engineered strain of vesicular stomatitis virus (VSV), a small RNA virus repurposed as an oncolytic agent—a virus designed to selectively infect and kill cancer cells while sparing normal tissue. The engineered virus carries two additional genes: interferon-beta, a natural antiviral signaling protein, and the sodium-iodide symporter (NIS), a transporter protein that normally allows thyroid cells to take up iodide. Inserting interferon-beta into the viral genome exploits a common feature of tumor biology: many cancer cells have defective antiviral interferon signaling, which allows the virus to replicate preferentially within tumors while triggering protective interferon responses in healthy tissue. This dual behavior improves the safety margin of a virus that could otherwise cause off-target toxicity. The NIS gene serves as a reporter, allowing infected tissue to take up radioactive iodine tracers, so that viral spread and tumor localization can be visualized noninvasively. Beyond direct tumor cell killing (oncolysis), the induced interferon response also activates innate and adaptive immune cells, contributing an immune-mediated antitumor effect. This combination broadly matters in oncology because it merges direct cytotoxic viral therapy with immune stimulation and built-in imaging capability, addressing both efficacy and monitoring challenges inherent to virotherapy.